KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Current Assets (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Current Assets for 17 consecutive years, with $26.0 billion as the latest value for Q4 2025.

  • Quarterly Current Assets rose 9.89% to $26.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.0 billion through Dec 2025, up 9.89% year-over-year, with the annual reading at $26.0 billion for FY2025, 9.89% up from the prior year.
  • Current Assets hit $26.0 billion in Q4 2025 for Abbott Laboratories, up from $24.8 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $26.0 billion in Q4 2025 to a low of $21.8 billion in Q1 2021.
  • Historically, Current Assets has averaged $23.8 billion across 5 years, with a median of $23.6 billion in 2023.
  • Biggest five-year swings in Current Assets: soared 40.77% in 2021 and later decreased 10.13% in 2023.
  • Year by year, Current Assets stood at $24.2 billion in 2021, then increased by 4.06% to $25.2 billion in 2022, then fell by 10.13% to $22.7 billion in 2023, then increased by 4.35% to $23.7 billion in 2024, then grew by 9.89% to $26.0 billion in 2025.
  • Business Quant data shows Current Assets for ABT at $26.0 billion in Q4 2025, $24.8 billion in Q3 2025, and $24.5 billion in Q2 2025.